13-48463835-G-T
Variant summary
Our verdict is Likely pathogenic. Variant got 6 ACMG points: 6P and 0B. PM1PM2PP5_Moderate
The ENST00000267163.6(RB1):c.2211G>T(p.Glu737Asp) variant causes a missense, splice region change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. E737K) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000267163.6 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RB1 | NM_000321.3 | c.2211G>T | p.Glu737Asp | missense_variant, splice_region_variant | 21/27 | ENST00000267163.6 | NP_000312.2 | |
RB1 | NM_001407165.1 | c.2211G>T | p.Glu737Asp | missense_variant, splice_region_variant | 21/27 | NP_001394094.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RB1 | ENST00000267163.6 | c.2211G>T | p.Glu737Asp | missense_variant, splice_region_variant | 21/27 | 1 | NM_000321.3 | ENSP00000267163.4 | ||
RB1 | ENST00000650461.1 | c.2211G>T | p.Glu737Asp | missense_variant, splice_region_variant | 21/27 | ENSP00000497193.1 | ||||
RB1 | ENST00000643064.1 | c.192+82392G>T | intron_variant | ENSP00000496005.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 27
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Retinoblastoma Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Mar 17, 2018 | For these reasons, this variant has been classified as Pathogenic. Other variants affecting this nucleotide (c.2211G>C and c.2211G>A) have been determined to be pathogenic (PMID: 18181215, 19390654, 22328814, 12541220, 9341870). This suggests that this nucleotide is important for normal RNA splicing, and that other variants at this position may also be pathogenic. Nucleotide substitutions within the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with RB1-related disease, but has been observed to be de novo in an individual affected with bilateral retinoblastoma (Invitae). This variant is not present in population databases (ExAC no frequency). This sequence change replaces glutamic acid with aspartic acid at codon 737 of the RB1 protein (p.Glu737Asp). The glutamic acid residue is highly conserved and there is a small physicochemical difference between glutamic acid and aspartic acid. This variant also falls at the last nucleotide of exon 21 of the RB1 coding sequence, which is part of the consensus splice site for this exon. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at